Travel Vaccines Market Competitor Analysis And Overview 2024-2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Travel Vaccines Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The travel vaccines market size has grown strongly in recent years. It will grow from $4.41 billion in 2023 to $4.79 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increased international travel, government initiatives for travel health, globalization of diseases, growing awareness among travelers, expansion of travel and tourism industry..

The travel vaccines market size is expected to see strong growth in the next few years. It will grow to $6.79 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to increasing frequency of business travel, emerging infectious disease threats, government regulations and entry requirements, rising demand for exotic destinations, collaboration between governments and pharmaceutical companies.. Major trends in the forecast period include tailored vaccination strategies, expansion of market to non-endemic regions, adoption of digital health technologies, regulatory support and streamlined approvals, innovative developments.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=11918&type=smp

Market Segmentation:
The travel vaccines market covered in this report is segmented -
1) By Disease: Hepatitis A, Diphtheria, Pertussis, And Tetanus (DPT), Yellow Fever, Typhoid, Hepatitis B, Measles And Mumps, Rabies, Meningococcal, Other Diseases,
2) By Composition: Mono Vaccines, Combination Vaccines
3) By Booking Channel: Online Booking, In-Person Booking
4) By Application: Domestic Travel, Outbound Travel

Major Driver - Surge In Travel And Tourism Drives Growth Of The Travel Vaccine Market
The increase in travel and tourism is expected to propel the growth of the travel vaccine market going forward. Travel and tourism refer to the movement of people or things, including vehicles like trains, boats, airplanes, and other conveyances, between various remote geographic areas. Travel vaccines are helpful for tourists and travelers by keeping them safe and healthy while they are traveling abroad. For instance, in January 2023, according to the United Nations World Tourism Organization (UNWTO), a Spain-based intergovernmental tourism-promoting organization, more than 900 million tourists traveled abroad in 2022, double the amount recorded in 2021 but still 63% higher than pre-pandemic levels. Therefore, the increase in travel and tourism is driving the growth of the travel vaccine market.

Competitive Landscape:
Major companies operating in the travel vaccines market report are Pfizer Inc., Johnson and Johnson, Merck & Co. Inc., Novartis AG, Sanofi SA, AstraZeneca PLC., GlaxoSmithKline plc, Moderna Inc., BioNTech Europe GmbH, Biological E. Limited, Bausch Health Companies Inc., Takeda Pharmaceutical Company Limited, Novavax Inc., Emergent BioSolutions UK, Serum Institute of India Pvt. Ltd., Dynavax Technologies, Bavarian Nordic A/S, Valneva SE, Panacea Biotec, Vabiotech, Inovio Pharmaceuticals, Bharat Biotech International Limited, Altimmune Inc., Bio Farma, Vaxart Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/travel-vaccines-global-market-report

Top Trend - Takeda's Qdenga Approval Marks A Milestone In Travel Vaccine Innovation
Product innovation is a key trend gaining popularity in the travel vaccine market. Major companies operating in the travel vaccine market are developing innovative vaccines sustain their position in the market. For instance, in August 2022, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, got the approval for QDENGA (Dengue Tetravalent Vaccine) (TAK-003), for the prevention of dengue sickness caused by any serotype in people aged six to 45 from Indonesia National Agency for Drug and Food Control. Regardless of a person's prior exposure to the disease, QDENGA showed three years after immunization that it remained to provide overall protection against dengue sickness and hospitalization.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Travel Vaccines Market Characteristics
3. Travel Vaccines Market Trends And Strategies
4. Travel Vaccines Market - Macro Economic Scenario
5. Travel Vaccines Market Size And Growth
…..
27. Travel Vaccines Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

"Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

"About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.